2022-06-14| Special

Big Success without Big Pharma: Making Deals as a Small Firm

by Eduardo Longoria
Share To

As part of the June 7th-9th RESI conference four panelists moderated by Rachel Zolot Schwartz of Volostra Therapeutics gathered to discuss alternatives to big pharma partners when wanting to do development deals as a small firm.

The speakers include:

To start off the discussion the panel put in their ideas about the market’s condition and if it is changing their outlook on deal making. The panel provided an optimistic outlook for companies looking to get funding in the current market. As a rule, market capitalizations are falling and generally lowering the average market cap needed to be seen as a company worth examining. According to the panelists $25million market capitalization is sufficient in some cases to enter a pipeline for a deal.


It's free! Log in now to read

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol
Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.
Scroll to Top